CARLSBAD, California., December 19, 2025 /PRNewswire/ — With the CDC’s Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testing for hepatitis B, laboratories are facing new demands to assess immunity more effectively. Paintera leader in targeted proteomics, today introduced its ViraScreen-Core™ multiplex antibody test, an established test already in use by CLIA-certified laboratories, as a ready-to-use solution to support this evolving public health guidance. Designed for both serum and salivaThe test provides unparalleled flexibility for laboratories to adapt to these changes while meeting broader infectious disease testing needs.
Hepatitis B remains a major global health challenge, but immunity testing has historically been limited by cost, operational complexity, and single analyte approaches. Pictor’s ViraScreen-Core™ test enables simultaneous detection of antibodies to hepatitis B, HIV-1, HIV-2 and hepatitis C from a single sample, reducing turnaround times, conserving patient samples and supporting evidence-based clinical decision-making.
“Antibody testing gives laboratories flexibility as public health guidelines evolve,” said Dr. Jamie Platt, CEO of Pictor. “By offering a multiplex test that works with both serum and saliva, we aim to help laboratories move toward evidence-based immunity assessment without adding operational complexity. »
Pictor has performed paired serum and saliva studies demonstrating high concordance, confirming saliva as a reliable testing matrix. This capability can help reduce barriers to testing, particularly in pediatric, community health, and decentralized settings where blood draws can be difficult.
“Pictor’s ViraScreen-Core™ test represents a valuable addition to our clinical laboratory,” said Dr. Andrew Brown, Chief Commercial Officer of Sirona Dx. “Compatibility with saliva samples expands the environments in which testing can be performed, while the multiplex format supports streamlined and efficient workflows for infectious disease testing. »
Pictor is actively raising capital to support the continued commercialization, test menu expansion and U.S. deployment of its targeted proteomics platform, building on the early adoption of its technology in the laboratory.
For more information about Pictor’s ViraScreen-Core™ test, visit www.pictordx.com
About Pictor
Pictor is a leader in flexible, targeted proteomics, delivering next-generation multiplex solutions that empower clinical laboratories, diagnostic manufacturers and veterinary providers around the world. Powered by its patented PictArray™ platform, PictImager™ and AI-powered Pictorial™ software, Pictor delivers deeper insights from a single sample, delivering faster, more affordable and scalable results.
From infectious diseases to oncology, Pictor’s innovative technology advances human and animal health, enabling breakthroughs in clinical decision-making. Headquartered in San Diego, Pictor Holdings Inc. is committed to driving innovation through solutions designed for unmatched performance, profitability and productivity.
Learn how Pictor is shaping the future of proteomic testing at www.pictordx.com.
About Sirona Dx
Sirona Dx is a technical CRO shaping the next generation of diagnostics to accelerate therapeutic development and advance precision medicine initiatives. Built at the intersection of science and technology, Sirona Dx is driven by innovation because improved diagnostics lead to better outcomes. For more information, visit www.sironadx.com.
Disclaimer / Forward-Looking Statements
This press release does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities and may not be relied upon in connection with the purchase or sale of any securities of the Company. This release may contain forward-looking statements regarding, among other things, the Company’s expansion plans, product development initiatives, financing objectives, strategic partnership results and market positioning. These statements are forward-looking statements and there can be no assurance that the results stated or implied by these forward-looking statements will actually be realized or achieved by the Company. Forward-looking statements may be based on management’s assumptions that may prove to be incorrect. The Company’s forecasts may not be realized for a variety of reasons, as the Company’s business is subject to significant risks and potential events beyond its control that could cause material differences between anticipated and actual results.
Media Contact:
Kelly Krueger
415-235-5031
Kelly.krueger@audacityhealth.com
SOURCE Pictor Holdings Inc.
